4.7 Article

WT-PE: Prime editing with nuclease wild-type Cas9 enables versatile large-scale genome editing

期刊

出版社

SPRINGERNATURE
DOI: 10.1038/s41392-022-00936-w

关键词

-

资金

  1. National Natural Science Foundation of China [U19A2002, 81771220, 81974238]

向作者/读者索取更多资源

A novel prime editor, WT-PE, was designed in this study by fusing reverse transcriptase (RT) to nuclease wild-type Cas9, enabling efficient editing of large genomic fragments. The WT-PE system introduced a double strand break (DSB) and a single 3' extended flap in the target site, and coupled with paired prime editing guide RNAs (pegRNAs), it achieved bi-directional prime editing, allowing versatile and efficient large-scale genome editing. This WT-PE system has great potential for modeling or treating diseases related to large-fragment aberrations.
Large scale genomic aberrations including duplication, deletion, translocation, and other structural changes are the cause of a subtype of hereditary genetic disorders and contribute to onset or progress of cancer. The current prime editor, PE2, consisting of Cas9-nickase and reverse transcriptase enables efficient editing of genomic deletion and insertion, however, at small scale. Here, we designed a novel prime editor by fusing reverse transcriptase (RT) to nuclease wild-type Cas9 (WT-PE) to edit large genomic fragment. WT-PE system simultaneously introduced a double strand break (DSB) and a single 3 ' extended flap in the target site. Coupled with paired prime editing guide RNAs (pegRNAs) that have complementary sequences in their 3 ' terminus while target different genomic regions, WT-PE produced bi-directional prime editing, which enabled efficient and versatile large-scale genome editing, including large fragment deletion up to 16.8 megabase (Mb) pairs and chromosomal translocation. Therefore, our WT-PE system has great potential to model or treat diseases related to large-fragment aberrations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据